Saxagliptin tablets belong to hypoglycemic agents?
Saxagliptin is a competitive inhibitor of dipeptidyl peptidase 4 that reduces the rate of inactivation of pancreatic islet hormones and increases its blood concentration, thereby reducing glucose-dependent manner in patients with type 2 diabetes with fasting and postprandial Blood glucose concentration. Postprandial release from the small intestine into the blood of pancreatic islet hormones increased, Saxagliptin such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), to promote pancreatic beta cells with glucose-dependent Sexual release of insulin, and DPP4 will inactivate it. GLP-1 also inhibits pancreatic α-cell secretion of glucagon, thereby inhibiting liver glucose production. The GLP-1 concentration in type 2 diabetic patients decreased, but the effect of GLP-1 on pancreatic islet was still present.
The advent of dipeptidyl peptidase-4 (DPP-4) inhibitors is a fruitful result of the 21st century pharmacy study, which is unique in its pathways, Saxagliptin bypassing pancreatic islet beta cells and insulin, by inhibiting DPP-4 activity to prolong hyperglycemia (GLP-1) and the promotion of insulin secretion, thereby reducing blood glucose levels, this paper on its characteristics and clinical application of the evaluation. Methods: The domestic and foreign literatures were analyzed. RESULTS AND CONCLUSION: DPP-4 inhibitors control the stability of blood glucose by inhibiting the degradation of endogenous GLP-1, increasing the level of GLP-1, Saxagliptin and promoting glucose-dependent insulin secretion and inhibiting glucagon production. DPP-IV inhibitors have an advantage that does not affect body weight and do not increase the risk of hypoglycemia and play an increasingly important role in the treatment of type 2 diabetes.